Anticoagulation
Phase 1Small molecule
Anticoagulation is one of 96 small molecule programs targeting Atrial Fibrillation. It is currently in Phase 1.
5
Indications
8
Total Trials
1
Active Trials
95
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
137 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Calquence
AstraZenecaPreclinical
Anticoagulation
HHospital Álvaro Cunqueiro
Phase 1
Rituxan
RochePreclinical
Coumadin
AAbbott
Preclinical
Brukinsa
BBeOne Medicines
Preclinical
Imbruvica
PPharmacyclics LLC.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atrial Fibrillation1 trial
Oral Anticoagulation1 trial
Anticoagulation1 trial
Portal vein thrombosis1 trial
TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis
Unknown status·—·N/A·NCT02485184·120 enrolled
3 more indications
Venous thrombosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anticoagulation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- HHospital Álvaro Cunqueiro